The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: connecting the dots.
Costello LC, Franklin RB. · 2006
Read The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: connecting the dots. by Costello LC, Franklin RB. (2006) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc1481516.txt.
Introduction
The prostate gland makes huge amounts of citrate, a fruit acid, and stores zinc to do it. Costello and Franklin reviewed in 2006 how that odd chemistry flips in prostate cancer. Healthy gland cells hoard zinc, which blocks citrate burning. Cancer cells lose that hoarding skill.
Without zinc, the cells burn citrate for energy instead. A gene for a zinc intake pump, Zip1, fades in cancer cells. Costello frames zinc as a tumor suppressor, a brake on growth. The review ties lab and clinical proof into one story. It urges more heed to metabolism, long ignored in prostate cancer work.
Catalog record
| CREATOR | Costello LC, Franklin RB. |
|---|---|
| YEAR | 2006 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 54 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: connecting the dots By Leslie C Costello, Renty B Franklin Published in: Molecular Cancer DOI: 10.1186/1476-4598-5-17 ABSTRACT Background The genetic and molecular mechanisms responsible for and associated specifically with the development and progression of malignant prostate cells are largely unidentified. In addition, despite its implication in virtually all malignant cells, the role of altered cellular metabolism as an essential factor in prostate malignancy has been largely ignored. Moreover, the intermediary metabolism of normal prostate as well as malignant prostate cells is among the least studied and most poorly understood of all mammalian cells. Some important factors, especially the role of zinc, have been identified and implicated in the development and progression of prostrate malignancy. In this review, we provide a current and updated integrated assessment of the relationships of intermediary metabolism in normal prostate and in prostate cancer. The experimental and clinical evidence that leads to the formulation of concepts of normal and malignant prostate metabolism is presented. The evidence for a concept of zinc as a tumor suppressor agent and Zip1 zinc transporter as a tumor-suppressor gene is described. Results The specialized function of the normal prostate glandular epithelium to produce and secrete enormously high levels of citrate involves and requires unique intermediary metabolism activities that are not generally associated with other normal mammalian cells. The accumulation of zinc by these cells is an essential factor in this unique metabolic relationship. In malignancy, the normal zinc-accumulating citrate-producing epithelial cells are metabolically transformed to citrate-oxidizing cells that lose the ability to accumulate zinc. A genetic alteration in the expression of ZIP1 zinc transporter is associated with this metabolic transformation. These genetic/metabolic relationships have important consequences on citrate-related metabolism, bioenergetics, cell proliferation and invasive capabilities of the malignant cells, which result in tumor-suppression characteristics. Conclusion The genetic/metabolic relationships in normal prostate glandular epithelium are driven by the unique function to accumulate and secrete citrate. The genetic/metabolic transformation of the prostate malignant cells is driven by the metabolic/bioenergetic, growth/proliferative, and invasive/migration requirements of the malignant process. Zinc is critical to these relationships. An understanding of these genetic/metabolic relationships provides new directions and opportunities for development of regimens for the prevention and treatment of prostate cancer. Important insight into the genetic/metabolic requirements of the prostate malignant process is now evolving. Most importantly at this time, an appreciation and recognition of the genetic/metabolic significance and implications in the development of prostate malignancy is imperative; and much needed research in this area is essential. Hopefully, this review will help to achieve these goals. INTRODUCTION About 230,000 males are expected to be identified with prostate cancer in the next year that will result in about 30,000 deaths. Despite the extensive clinical and experimental studies over the recent decades, the pathogenesis of prostate cancer remains unknown. The genetic and molecular mechanisms responsible for and associated specifically with the development and progression of malignant prostate cells are largely unidentified [[1,2] for reviews]. Coupled with this is the largely ignored role of altered cellular metabolism as an essential factor in prostate malignancy; although transformations of metabolism are implicated in virtually all malignant cells [3-8]. The combination of genetic/molecular/metabolic relationships is required to identify critical events in the prostate malignancy process. Such studies are beginning to reveal an essential understanding of the development and progression of prostate cancer. This review will provide a current and updated integrated assessment of the relationships of intermediary metabolism in normal prostate and in prostate cancer. Much of the description of important contributions of earlier investigators and early studies that should be recognized is presented in our previous reviews [8-12]; and will not be repeated except where relevant to the present discussion. We will describe the experimental and clinical evidence that leads to the formulation of concepts of normal and malignant prostate metabolism. Important gaps, unresolved issues, and areas of required future studies relating to prostate intermediary metabolism will be identified. The review will culminate in defining important genetic/metabolic events in the development and progression of prostate malignancy. The evidence for a concept of zinc as a tumor suppressor agent and ZIP1 zinc transporter as a tumor-suppressor gene will be described. The clinical/translational application of these relationships is also presented. The totality of this presentation is intended first to be informative. Hopefully, the presentation will be stimulating and even provocative; so that more attention is directed to this subject matter and other investigators might become involved. Finally, we hope to convince the clinical and scientific community-at-large of the importance of metabolic relationships in the development and progression of prostate cancer, and the relevance to new approaches to detection, treatment, and perhaps prevention of prostate cancer. Axioms of relationships of cellular activity, cellular metabolism, and malignancy The following are important generalizations that we consider to be axiomatic. 1). In all cells, the existing cellular intermediary metabolism provides the bioenergetic/synthetic/catabolic requirements that are essential for the manifestation of the cells' current activities (function, growth, proliferation). 2). When a cell's activity changes, its metabolism must also be adjusted consistent with any newly established bioenergetic/synthetic/catabolic requirements 3). Malignant cells exhibit a parasitic existence. They have no specialized function other than the activities essential for their generational propagation (growth and proliferation), which occurs at the expense of their host. 4). Malignant cells are derived from normal cells that have undergone a genetic transformation to a neoplastic cell phenotype that is endowed with malignant potential. 5). Manifestation of the malignant potential of the neoplastic cell necessitates alterations in its metabolism (ie a metabolic transformation) to provide the bioenergetic/synthetic requirements of malignancy. 6). In the absence of the metabolic transformation, the neoplastic cell will not progress to complete malignancy. Conversely, the metabolic transformation, in the absence of the genetic transformation to a neoplastic malignant cell, will not cause malignancy. 7). Common to all malignant cells is the metabolic requirement for de novo lipogenesis/cholesterogenesis for membraneogenesis that is essential for their proliferative existence. These axioms define a relationship represented in figure 1 that we propose is applicable to all malignancies. [Figure: The concept of genetic/metabolic development of malignant cells.] Normal prostate function and associated intermediary metabolism: net citrate production The human prostate gland is a complex organ comprised of different zones that have different embryological origin and different functional activities. The focus of this presentation is the peripheral zone, which comprises about 70% of the gland, and is the major functional component. Most importantly, this is the major region of malignancy. The primary function of the prostate gland is the production and secretion of prostatic fluid [8-12]. The major component of the prostatic fluid is its extraordinarily high concentration of citrate, which ranges from ~40–150 mM as contrasted with ~0.2 mM citrate in blood plasma (Table 1). Correspondingly, normal peripheral zone tissue citrate levels range from ~10,000–15,000 nmols/gram as contrasted with other tissues that generally contain ~250–450 nmols/gram. [Table: REPRESENTATIVE PROSTATE LEVELS] The function of prostate citrate production is achieved by the activity of highly specialized glandular epithelial cells that have evolved for the capability to accumulate and secrete citrate, which we refer to as "net citrate production". This capability does not exist in other mammalian cells. Consequently the intermediary